Cabometyx™ May Be ‘New Treatment Option’ for Liver Cancer
(February 20, 2018)
CancerConnect News: Treatment with Cabometyx (cabozantinib) significantly improved outcomes in patients with advanced hepatocellular carcinoma (HCC), leading researchers to suggest that it could offer a new treatment option for this patient population. ... Continue Reading
Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer
(February 15, 2018)
CancerConnect News: According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About... Continue Reading
Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer
(May 18, 2017)
Results from the CheckMate 040 clinical trial have been recently reported and found that Opdivo (nivolumab), an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates in patients with... Continue Reading
First New Drug for Liver Cancer in a Decade: Stivarga
(May 8, 2017)
The US Food and Drug Administration (FDA) has expanded the indication for Stivarga (regorafenib) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug Nexavar. Expansion of Stivarga, ‘s... Continue Reading
February: Gallbladder and Bile Duct Awareness Month
(February 18, 2016)
Located underneath the liver, the gallbladder is responsible for the concentration and storage of bile which helps to digest the fats in food as they pass through the intestines. Bile is either released from the liver directly into ducts that carry it... Continue Reading
Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents
(February 11, 2016)
The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency... Continue Reading
Infection with Hepatitis C Increases Risk of Cirrhosis
(March 10, 2015)
People who are infected with the hepatitis C virus (HCV) have a higher risk for developing the liver disease cirrhosis, particularly within the first five years after infection. These findings were released in JAMA Internal Medicine. Cirrhosis, or late-stage... Continue Reading
Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen
(July 31, 2014)
According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients affected... Continue Reading
Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation
(May 27, 2014)
The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading
Coffee Cuts Risk of Liver Cancer
(November 8, 2013)
Good news for coffee addicts—new research has found that regular coffee consumption can reduce the risk of liver cancer by 40 percent. In fact, the study—published in Clinical Gastroenterology and Hepatology—found that people who consume more than... Continue Reading
Latest Liver Cancer News By Stage
Hepatocellular Carcinoma Liver Cancer
Antiviral Therapy May Reduce the Risk of Tumor Recurrence in HBV-Related Liver Cancer
(November 26, 2012)
Patients with hepatitis B-related liver cancer who receive antiviral drugs after curative surgery have a lower risk of recurrence compared to those who do not receive antiviral therapy, according to the results of a study published in the Journal of the... Continue Reading
Sutent® Not Effective for Advanced Liver Cancer
(July 10, 2009)
In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology. Hepatocellular carcinoma... Continue Reading
Women with Hypothyroidism at Increased Risk of Liver Cancer
(June 22, 2009)
Women with Hypothyroidism at Increased Risk of Liver Cancer Long-term hypothyroidism in women significantly increases the risk of developing hepatocellular carcinoma (liver cancer), according to the results of a study published in Hepatology.[1] The liver... Continue Reading
Increased Risk of Liver Cancer for Patients with Cirrhosis Who Overexpress EGF
(March 8, 2009)
Increased Risk of Liver Cancer for Patients with Cirrhosis Who Overexpress EGF According to an article recently published in the Journal of the American Medical Association, patients with cirrhosis of the liver who overexpress epithelial growth factor... Continue Reading
Nexavar® Added to Treatment Guidelines for Liver Cancer
(March 8, 2009)
Nexavar® Added to Treatment Guidelines for Liver Cancer The drug Nexavar® (sorafenib) has been added to the list of treatment options for patients with liver cancer who are not eligible for a liver transplant. This was reported in a recent presentation... Continue Reading
More Hepatocellular Carcinoma Liver Cancer
Recurrent Liver Cancer
Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation
(May 27, 2014)
The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading
Cabozantinib Shows Promise against Bone Metastases
(May 31, 2011)
The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 annual... Continue Reading
Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain
(November 16, 2010)
Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading
More Recurrent Liver Cancer
Screening/Prevention Liver Cancer
Infection with Hepatitis C Increases Risk of Cirrhosis
(March 10, 2015)
People who are infected with the hepatitis C virus (HCV) have a higher risk for developing the liver disease cirrhosis, particularly within the first five years after infection. These findings were released in JAMA Internal Medicine. Cirrhosis, or late-stage... Continue Reading
Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen
(July 31, 2014)
According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients affected... Continue Reading
Coffee Cuts Risk of Liver Cancer
(November 8, 2013)
Good news for coffee addicts—new research has found that regular coffee consumption can reduce the risk of liver cancer by 40 percent. In fact, the study—published in Clinical Gastroenterology and Hepatology—found that people who consume more than... Continue Reading
Statins Linked to Lower Risk of Liver Cancer in Hepatitis C
(May 8, 2013)
People infected with chronic hepatitis C are less likely to develop liver cancer if they are taking statins (cholesterol-lowering drugs), according to the results of a study published in the Journal of Clinical Oncology.[1] The liver is the largest organ... Continue Reading
Aspirin Continues to Look Promising for Cancer Prevention
(March 26, 2012)
A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading
More Screening/Prevention Liver Cancer
Stage IV Liver Cancer
Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation
(May 27, 2014)
The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading
Nexavar Superior to Sutent in Liver Cancer
(June 23, 2011)
Nexavar® (sorafenib) provides superior overall survival to Sutent® (sunitinib) in the treatment of hepatocellular (liver) cancer. These results were presented at the 2011 annual American Society of Clinical Oncology (ASCO) meeting. Hepatocellular carcinoma... Continue Reading
Cabozantinib Shows Promise against Bone Metastases
(May 31, 2011)
The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 annual... Continue Reading
FDA Grants Orphan Drug Status to Investigational Liver Cancer Drug
(May 2, 2011)
PV-10—an investigational liver cancer drug—has been designated an orphan drug by the US Food and Drug Administration (FDA). The orphan drug designation is intended to encourage the development of drugs for rare diseases by providing incentives for... Continue Reading
Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain
(November 16, 2010)
Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading
More Stage IV Liver Cancer
Stages I-III Liver Cancer
Antiviral Therapy May Reduce the Risk of Tumor Recurrence in HBV-Related Liver Cancer
(November 26, 2012)
Patients with hepatitis B-related liver cancer who receive antiviral drugs after curative surgery have a lower risk of recurrence compared to those who do not receive antiviral therapy, according to the results of a study published in the Journal of the... Continue Reading
Nexavar Superior to Sutent in Liver Cancer
(June 23, 2011)
Nexavar® (sorafenib) provides superior overall survival to Sutent® (sunitinib) in the treatment of hepatocellular (liver) cancer. These results were presented at the 2011 annual American Society of Clinical Oncology (ASCO) meeting. Hepatocellular carcinoma... Continue Reading
Combination Chemotherapy Improves Survival with Biliary Tract Cancer
(May 17, 2010)
According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than... Continue Reading
Sutent® Not Effective for Advanced Liver Cancer
(July 10, 2009)
In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology. Hepatocellular carcinoma... Continue Reading
Differences in IMRT Radiation Doses May Complicate Study Results in Liver Cancer
(March 8, 2009)
Differences in IMRT Radiation Doses May Complicate Study Results in Liver Cancer Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies... Continue Reading
More Stages I-III Liver Cancer